Loading
Apyx Medical Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 03 Mar 2025.
Apyx Medical Corp: what insiders have been doing
Every trade that managers of Apyx Medical Corp disclose to SEC (Form 4) is tracked on this page. The company sits in the Health Care sector. In the past year (18 October 2025 to 18 October 2026), 7 filings came from 4 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.
Insider buying of Apyx Medical Corp has been absent for the past year. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4.
Across the 5,814 companies tracked on its exchange, the median is 19 filings; at 7 filings, this issuer sits below that mark. The full history, which starts in 2022, counts 5 purchases against no sales.
Other companies in the same sector with recent insider buying flagged by our signals: Cooper Companies, Inc. and Anixa Biosciences Inc. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
23
Thresholds
n/a
Buy Volume
€101,929
5 ops. · all time
Sell Volume
n/a
n/a
Since the insiders bought
- +177.3%Entry US$1.19 · Close at T+365 US$3.30
- -39.7%Entry US$2.09 · Close at T+365 US$1.26
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,331 of 24,148 companies
23.9
score / 100
Value17
Quality31
FCF yld-8.5%
Earn yld-10%
EV/EBITDA·
ROE-91%
Gross mgn63%
Net mgn-21%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$2.57
Analyst consensus
6 analysts1.33/5
US$6.00Target US$6.50(+153%)US$8.00
Income statement
RevenueUS$52.8M
Gross profitUS$33M63% margin
EBITDA-US$4.6M-9% margin
Net income-US$11.2M-14.8% margin
Valuation
PER (forward)-10.2x
P/Book10.2x
Beta1.45
Balance sheet & cash
Market capUS$108.3M
Total debtUS$39.3M
Free Cash Flow-US$9.1M
Debt / Equity357%
Profitability & ownership
ROE-90.7%
ROA-3.7%
% insiders13.5%
% institutions50.5%
Last declaration on 2 July 2026
Declarations23 total
12,000 sharesCommon StockSEC:0001493152-26-031944:0
5,024 sharesCommon StockSEC:0001493152-26-031944:1
15,000 sharesCommon StockSEC:0001493152-26-029122:0
10,533 sharesCommon StockSEC:0001493152-26-029122:1
450,000 sharesRestricted Stock UnitsSEC:0001493152-26-028771:0
37,000 shares@ US$1.8043.3% of flowCommon StockSEC:0001493152-26-010632:0
12,000 shares@ US$1.80100.0% of flowCommon StockSEC:0001493152-26-004254:0
6,000 shares@ US$1.1336.8% of flowCommon StockSEC:0001493152-25-008863:0
Canonical exit: 11 Nov 2024 (T+90)
5,336 shares@ US$1.1332.8% of flowCommon StockSEC:0001493152-24-031725:0
Canonical exit: 11 Nov 2024 (T+90)
2,500 shares@ US$2.1930.4% of flowCommon StockSEC:0001493152-23-044805:0
Canonical exit: 11 Mar 2024 (T+90)
50,000 shares@ US$1.5786.1% of flowCommon StockSEC:0001493152-23-041501:0
Canonical exit: 12 Feb 2024 (T+90)
5,338 shares@ US$2.9714.8% of flowCommon StockSEC:0001493152-23-024899:0
15,000 shares@ US$1.77100.0% of flowCommon StockSEC:0000719135-23-000036:0
10,000 shares@ US$2.7950.2% of flowCommon StockSEC:0000719135-23-000030:0
7,173 shares@ US$9.4243.8% of flowCommon StockSEC:0000719135-23-000020:0
2,000 shares@ US$5.9313.9% of flowCommon StockSEC:0000719135-22-000084:0
Canonical exit: 27 Nov 2022 (T+90)
30,000 shares@ US$2.5456.7% of flowCommon StockSEC:0000719135-22-000055:0
4,000 shares@ US$2.5419.2% of flowCommon StockSEC:0000719135-22-000050:0
24,000 shares@ US$2.5463.2% of flowCommon StockSEC:0000719135-22-000053:0
30,000 shares@ US$2.54100.0% of flowCommon StockSEC:0000719135-22-000052:0
8,000 shares@ US$2.7922.0% of flowCommon StockSEC:0000719135-22-000037:0
6,000 shares@ US$2.7930.6% of flowCommon StockSEC:0000719135-22-000035:0
17,000 shares@ US$4.98100.0% of flowCommon StockSEC:0000719135-22-000024:0
23 of 23 declarations
About Apyx Medical Corp
Apyx Medical Corp is a company focused on developing medical technologies, including surgical and skin care devices. It emphasizes innovation in the healthcare and pharmaceutical sectors.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
